October 2026 moved money and courtroom risk in pharmaceutical class actions. Two Sandoz generic-drug settlements set consumer claim deadlines, while Texas closed an ADHD-drug case and judges split on Entresto, Vivitrol and Regeneron investor claims. An end-payer is the consumer or health plan that paid at the pharmacy counter, not the wholesaler in the middle. That distinction decides which Sandoz fund you can claim from and what proof you will need.
Table of Contents
- Do You Have a Sandoz Claim to File?
- What Did the Texas ADHD Settlement Decide?
- Which Pricing Cases Moved Forward — and Which Ended?
- Do Regeneron Investors Face an Immediate Deadline?
Do You Have a Sandoz Claim to File?
On Oct. 1, 2026, 48 state and territorial attorneys general asked a federal court to approve a $400 million settlement with Sandoz and Fougera. The New York Attorney General says the deal resolves generic-drug price-fixing and market-allocation claims. It covers purchases from May 2009 to December 2019. Sandoz will pay $320,560,180 plus interest over seven years for a $400 million total. It must add antitrust reforms, including yearly sales-staff training and a chief compliance officer. The New York Attorney General says consumer claims under that deal are due March 8, 2027, in its payment and deadline notice.
A separate $275 million Sandoz/Fougera deal covers end-payers in In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-MD-2724. OpenClassActions reports it received final approval on Sept. 26, 2025. Consumers and health plans must file the combined claim by Nov. 9, 2026, per its deadline update. Check which fund fits you:.
- bought generics in May 2009-December 2019 as a consumer or health plan — save pharmacy receipts and insurer statements
- watch which Sandoz form you use — the state and end-payer funds have different deadlines
- file early — Nov. 9, 2026 comes before March 8, 2027
What Did the Texas ADHD Settlement Decide?
On Oct. 1, 2026, Texas Attorney General Ken Paxton secured a $7.5 million settlement with Tris Pharma. The case resolved a 2023 whistleblower suit over ADHD drug Dyanavel XR, as reported in the state's settlement release.
Texas said Tris misrepresented the drug's efficacy to Medicaid providers. That harmed Texas taxpayers who fund Medicaid and children prescribed the drug. This was a state Medicaid recovery, not a consumer payout fund. Parents will not file a claim under this deal, but they can keep treatment records and ask the prescriber about documented care.
Which Pricing Cases Moved Forward — and Which Ended?
On Sept. 24, 2026, U.S. District Judge Lewis Liman dismissed a proposed class action by Iron Workers Local 580 over Entresto. MedPath Trial reports the union claimed Novartis improperly listed Patent No. 8,101,659 to delay generics and raise buyer prices. The Orange Book is the FDA list linking brand drugs to patents.
A day later, an addiction-treatment case went the other way. Bloomberg Government reports a Massachusetts federal judge largely denied Alkermes' bid to dismiss claims that it withheld a study from patent officials to protect Vivitrol. Monopoly claims by buyers of the addiction-treatment drug can proceed. Dismissal ends that Entresto theory unless appeal revives it. Survival does not prove Vivitrol liability; it only lets buyers seek proof. If you bought either drug, keep receipts but do not file yet.
Do Regeneron Investors Face an Immediate Deadline?
Pomerantz reminded investors with Regeneron losses of a class-action lawsuit and key deadline. Investors claim Regeneron and executives violated Securities Exchange Act Sections 10(b) and 20(a) in case 26-cv-06026, per the firm's investor deadline notice. The lead-plaintiff motion deadline was Sept. 14, 2026.
A lead plaintiff is the investor the court picks to direct the case. Only timely movants can seek to lead, and the suit remains an unproven allegation, not a finding of fraud. If you missed the date, track the docket for next rulings and avoid non-court ads seeking fees. If you filed timely, keep trade confirmations and wait for court appointment orders.
You Might Also Like
- Tenant Rights and PTFA Class Actions October 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Auto-Renewal and Subscription Class Actions October 2026 Update: What Changed, Why It Matters, and What to Watch Next
- What Is New With Credit Reporting Class Actions in October 2026? Latest court filings and settlement notices and Key Takeaways